Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), is used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia [13, 14]. Here, BTK is linked to Waldenstrom macroglobulinemia.